10 Result(s)

Article

Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged ≥ 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical Study

Topical treatments for atopic dermatitis (AD) used reactively often fail to achieve lasting disease control; many of these therapies are associated with safety concerns that limit long-term use. Crisaborole oi...

Lawrence F. Eichenfield, Richard G. Gower… in American Journal of Clinical Dermatology (2023)

Article

Impact of Crisaborole on Sleep Outcomes in Pediatric Patients with Mild-to-Moderate Atopic Dermatitis

Using data from three clinical trials, the effect of crisaborole treatment on sleep outcomes for pediatric patients with atopic dermatitis (AD) and their families was examined.

Joseph Fowler, Jeffrey Sugarman, Lawrence Sher, Chuanbo Zang… in Dermatology and Therapy (2023)

Article

Matching-Adjusted Indirect Comparison of Crisaborole Ointment 2% vs. Topical Calcineurin Inhibitors in the Treatment of Patients with Mild-to-Moderate Atopic Dermatitis

Crisaborole topical ointment, 2%, is a nonsteroidal, topical anti-inflammatory phosphodiesterase-4 (PDE4) inhibitor that is approved for the treatment of mild-to-moderate atopic dermatitis (AD). The objective ...

Howard Thom, Vincent Cheng, Edna Keeney, Maureen P. Neary… in Dermatology and Therapy (2022)

Article

Correction to: Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ 2 Years with Mild-to-Moderate Atopic Dermatitis

Bob Geng, Adelaide A. Hebert, Liza Takiya, Lauren Miller… in Dermatology and Therapy (2021)

Article

Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ 2 Years with Mild-to-Moderate Atopic Dermatitis

Atopic dermatitis (AD) is a chronic inflammatory skin disease often requiring long-term treatment. Crisaborole significantly improved global AD signs and symptoms in 28-day phase 3 studies of patients aged ≥ 2...

Bob Geng, Adelaide A. Hebert, Liza Takiya, Lauren Miller… in Dermatology and Therapy (2021)

Article

Translating the Investigator’s Static Global Assessment to the Eczema Area and Severity Index in Studies of Crisaborole for Atopic Dermatitis

Atopic dermatitis (AD) severity was measured in two phase 3 US studies of crisaborole ointment, 2%, in patients aged ≥ 2 years using the Investigator’s Static Global Assessment (ISGA), an FDA-recommended scale...

Jacob P. Thyssen, Chuanbo Zang, Maureen P. Neary… in Dermatology and Therapy (2021)

Article

Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1)

Crisaborole ointment, 2%, is a nonsteroidal phosphodiesterase 4 inhibitor for the treatment of mild-to-moderate atopic dermatitis (AD).

Joel Schlessinger, Julie S. Shepard… in American Journal of Clinical Dermatology (2020)

Article

Evaluation of disease activity in patients with rheumatoid arthritis treated with tofacitinib by RAPID3: post hoc analyses from two phase 3 trials

Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. We evaluated the relationship between disease activity, according to Routine Assessment of Patient Index Data 3 (RAPID3)...

Vibeke Strand, Eun Bong Lee, Yusuf Yazici, Ara Dikranian… in Clinical Rheumatology (2018)

Article

A phase 3 randomized, double-blind, multicenter comparative study evaluating the effect of etanercept versus methotrexate on radiographic outcomes, disease activity, and safety in Japanese subjects with active rheumatoid arthritis

The aim of this phase 3, double-blind study was to compare the radiographic and clinical effects of etanercept (ETN) versus methotrexate (MTX) over 52 weeks in Japanese subjects with active rheumatoid arthritis.

Tsutomu Takeuchi, Nobuyuki Miyasaka, Chuanbo Zang, Daniel Alvarez… in Modern Rheumatology (2013)